Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases

Eline A.J. Willemse, Charlotte E. Teunissen*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

Cerebrospinal fluid (CSF) reflects pathophysiological aspects of neurological diseases, where neuroprotective strategies and biomarkers are urgently needed. Therefore, biobanking is very relevant for biomarker discovery and evaluation for these neurological diseases. An important aspect of CSF biobanking is quality control, needed for e.g. consistent patient follow-up and the exchange of patient samples between research centers. Systematic studies to address effects of preanalytical and storage variation on a broad range of CSF proteins are needed and initiated. Important features of CSF biobanking are intensive collaboration in international networks and the tight application of standardized protocols. The current adoption of standardized protocols for CSF and blood collection and for biobanking of these samples, as presented in this chapter, enables biomarker studies in large cohorts of patients and controls. In conclusion, biomarker research in neurodegenerative diseases has entered a new era due to the collaborative and multicenter efforts of many groups. The streamlining of biobanking procedures, including sample collection, quality control, and the selection of optimal control groups for investigating biomarkers is an important improvement to perform high quality biomarker studies.

Original languageEnglish
Title of host publicationBiobanking in the 21st Century
PublisherSpringer International Publishing AG
Pages79-93
Number of pages15
Volume864
ISBN (Electronic)9783319205793
ISBN (Print)9783319205786
DOIs
Publication statusPublished - 2015

Publication series

NameAdvances in Experimental Medicine and Biology
PublisherSpringer New York
ISSN (Print)0065-2598

Cite this